Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
NCT07197008
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab
Sponsor
Li-kun Chen